| 0.7894 -0.073 (-8.42%) | 09-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1 |
1-year : | 1.08 |
| Resists | First : | 0.86 |
Second : | 0.92 |
| Pivot price | 0.83 |
|||
| Supports | First : | 0.75 |
Second : | 0.62 |
| MAs | MA(5) : | 0.81 |
MA(20) : | 0.84 |
| MA(100) : | 0.84 |
MA(250) : | 1.11  |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 53.6 |
D(3) : | 43.3 |
| RSI | RSI(14): 44.6 |
|||
| 52-week | High : | 3.86 | Low : | 0.44 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RANI ] has closed above bottom band by 9.1%. Bollinger Bands are 40.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.87 - 0.88 | 0.88 - 0.88 |
| Low: | 0.78 - 0.78 | 0.78 - 0.79 |
| Close: | 0.78 - 0.79 | 0.79 - 0.8 |
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
Fri, 18 Sep 2026
RANI Stock Price, Quote & Chart - ChartMill
Tue, 08 Sep 2026
Rani Therapeutics will appear in New York on Sept. 10 and 14 - stocktitan.net
Tue, 08 Sep 2026
Rani Therapeutics to Participate in Upcoming September Conferences - globenewswire.com
Sun, 16 Aug 2026
Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline - Yahoo Finance
Thu, 13 Aug 2026
Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update - Yahoo Finance
Fri, 31 Jul 2026
Vanguard Capital Management discloses 5,052,862 Rani Therapeutics (RANI) shares in ownership report - stocktitan.net
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 115 (M) |
| Shares Float | 84 (M) |
| Held by Insiders | 4.9 (%) |
| Held by Institutions | 46.7 (%) |
| Shares Short | 8,160 (K) |
| Shares Short P.Month | 8,850 (K) |
| EPS | -0.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.34 |
| Profit Margin | 0 % |
| Operating Margin | -516.9 % |
| Return on Assets (ttm) | -53 % |
| Return on Equity (ttm) | -172.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.04 |
| Sales Per Share | 0.04 |
| EBITDA (p.s.) | -0.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -6.08 |
| PEG Ratio | 0 |
| Price to Book value | 2.25 |
| Price to Sales | 18.67 |
| Price to Cash Flow | -4.5 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|